Articles by Will Pass
Dupilumab Improves Ear Outcomes in Patients With Nasal Polyps and Eosinophilic Otitis Media
Dupilumab may offer relief for patients with eosinophilic otitis media (EOM) and severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to investigators. Over 12 months, the agent improved both sinonasal outcomes and otologic outcomes, including the Chronic Otitis Media Outcome Test 15 value (COMOT-15), which showed a median decrease from 49 to 15, reported lead author Cosimo Galletti, MD, of the Kore University of Enna, Enna, Italy.
Food Allergy Blood Tests Keep Improving, but None Can Replace Oral Food Challenge
Blood tests for food allergy have become more specific over time, but none can yet replace the oral food challenge, which remains the gold standard for both diagnosis and threshold analysis, according to leading experts. Although component testing, which increases blood test specificity compared with older tests, is now a staple of routine practice, other attempts to deliver a better blood test have so far fallen short.
Standing Up More May Not Cut Risk for Cancer Death
Standing up is not enough. Taking breaks from long stretches of sitting is not, on its own, associated with a lower risk of dying from cancer, but replacing that sitting time with physical activity is, an accelerometer study of more than 91,000 adults showed. Over more than a decade of follow-up, cancer death occurred in 2.8% of participants in the highest quartile of daily sedentary time compared with 1.3% in the lowest quartile, reported senior author Frederick K.
Standing Up More May Not Cut Risk for Cancer Death
Health 1 hour ago A colorectal dietitian shares 2 foods she eats regularly and 1 she avoids to lower her cancer risk Business Insider - Kim Schewitz • 1h Sophie Medlin has been a colorectal dietitian for 20 years, and in that time she has made some changes to her diet to lower her risk of colon cancer. Medlin and her husband, who is a chef, cook most of their meals, meaning they mainly eat a diet of whole, unprocessed foods.
Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?
Adding a non-GLP-1 weight-loss drug could help breast cancer survivors achieve target weight loss when lifestyle intervention falls short, a phase 2 trial suggested. Among women who were unable to lose 5% of their body weight after 2 months of a behavioral program, adding naltrexone-bupropion to their treatment regimen helped 42% successfully achieve that 5% threshold.
Fecal Transplant Raises Peanut Tolerance in Some Allergic Adults
Oral fecal microbiota transplant (FMT) can increase the allergic threshold in some adults with peanut allergy, based on results of a phase 1 trial. Six of 15 highly peanut-allergic adults responded to the transplant, with their reaction threshold rising from approximately half a peanut to one to two peanuts, reported lead author Rima Rachid, MD, associate professor of pediatrics at Harvard Medical School and co-director of the Food Allergy Program at Boston Children’s Hospital in Boston.
Which Cancers Are Still More Deadly in Black vs White Patients?
The cancer mortality gap between Black and White individuals in the US has narrowed, but disparities in breast, uterine corpus, and prostate cancer specifically have remained wide or gotten worse, according to a new analysis. The excess cancer mortality rate among Black patients fell by 98.4 deaths per 100,000 in men and 21.7 deaths per 100,000 in women, when comparing the 1991-1995 period with the 2019-2023 period.
Un perfil de andrógenos en sangre podría diagnosticar endometriosis
De acuerdo con un estudio publicado en European Journal of Endocrinology. Las mujeres con endometriosis presentan un patrón característico de andrógenos en sangre que las diferencia de quienes no padecen la enfermedad, según un reciente estudio de casos y controles.[1] Estos hallazgos podrían dar lugar a una prueba no invasiva para una afección cuyo diagnóstico suele tardar años y que generalmente requiere confirmación quirúrgica, señaló el autor principal, Douglas Gibson, Ph. D.
Glioma Outcomes Shaped by Subtype More Than Treatment Sequence
Molecular subtype is more important than treatment sequence in shaping survival outcomes among patients with high-risk low-grade glioma (LGG), suggest long-term results of a randomized phase 3 trial. Among patients with astrocytoma, median overall survival (OS) remained the same regardless of whether the chemotherapy temozolomide (TMZ) or radiotherapy (RT) was used for frontline treatment. Similarly, among patients with oligodendroglioma, OS was comparable whether they started with RT or TMZ.
Lung Transplant for Lung Cancer: Promising, in Rare Cases
In findings that challenge long-standing beliefs, researchers have shown that bilateral lung transplant may extend the lives of selected patients with stage IV non-small cell lung cancer (NSCLC). Experts stress, however, that no one is calling it a cure — and that only a small fraction of patients would be candidates.
Distinct Blood Androgen Signature May Help Diagnose Endometriosis Without Surgery
Women with endometriosis have a distinct pattern of androgens in their blood that sets them apart from women without the disease, based on a recent case-control study. These findings could lead to a noninvasive test for a condition that often takes years to diagnose and typically requires surgical confirmation, according to senior author Douglas Gibson, PhD, of the University of Edinburgh, Edinburgh, Scotland.
Two Studies Link GLP-1 Use to Lower Breast Cancer Risk
GLP-1 receptor agonists (GLP-1 RAs) are associated with reduced incidence of breast cancer among women with overweight or obesity, according to two observational studies. One found that GLP-1 RA users had a roughly 30% lower incidence of breast cancer than was seen in matched nonusers. The smaller of the two, which followed more than 80,000 women at high risk for breast cancer, found a more modest 16% reduction.
GLP-1s Tied to Lower Cancer Risk in Patients With Obesity
Individuals with obesity without diabetes taking GLP-1 receptor agonists (RAs) may have a reduced risk for certain cancers, a new study suggests. The target trial emulation of more than 160,000 patients found that individuals receiving the medications had a 41% lower risk for obesity-associated cancers (OACs), with an even more substantial 68% risk reduction among men.
ASCO 2026 - Iza-Bren supera la chemioterapia nel trattamento di seconda linea del cancro esofageo
Il coniugato anticorpo-farmaco izalontamab brengitecan (iza-bren) migliora la sopravvivenza come terapia di seconda linea nei pazienti affetti da carcinoma squamoso dell'esofago (esophageal squamous cell carcinoma, ESCC) recidivante o metastatico, secondo i risultati provvisori di uno studio randomizzato di fase 3. Rispetto alla chemioterapia, iza-bren ha ridotto il rischio di morte del 36% e il rischio di progressione della malattia o di morte della metà.
Pocos fármacos contra el cáncer pediátrico llegan a la fase 3 o obtienen la aprobación
La mayoría de los fármacos contra el cáncer que entran en ensayos clínicos en niños y adolescentes no llegan a los ensayos de fase avanzada ni obtienen la aprobación regulatoria pediátrica, según los autores de una nueva investigación. Durante un periodo de 15 años, solo 17,7 % de los fármacos contra el cáncer que entraron en ensayos clínicos aptos para niños avanzaron a un ensayo pediátrico de fase 3.
La monoterapia con teclistamab mejoró la sobrevida en pacientes con mieloma previamente tratados
El uso de teclistamab se asocia con una mejor sobrevida libre de progresión (SLP) y sobrevida global (SG) que los esquemas de tratamiento estándar para el mieloma múltiple recidivante o refractario, según los resultados del primer ensayo de fase 3 para evaluar el anticuerpo biespecífico contra el antígeno de maduración de células B (BCMA) como monoterapia.
Asandeutertinib supera a osimertinib en el tratamiento del cáncer de pulmón de células no pequeñas con mutación EGFR y metástasis cerebrales
El inhibidor del receptor del factor de crecimiento epidérmico (EGFR) en fase de investigación, asandeutertinib, se asoció a una mejor tasa de respuesta objetiva intracraneal (TROi) y a una mejor sobrevida libre de progresión intracraneal (SLPi) que osimertinib como tratamiento de primera línea en pacientes con cáncer de pulmón de células no pequeñas (CPCNP) con mutación del EGFR y metástasis cerebrales, según mostraron los resultados provisionales de un ensayo de fase 2.
Abemaciclib Slows Progression of Advanced Liposarcoma
The CDK4/6 inhibitor abemaciclib significantly delays progression of advanced dedifferentiated liposarcoma, in findings that experts said open up a new treatment option for patients who currently have few. Among 108 patients in a phase 3 trial, abemaciclib extended median progression-free survival to nearly 10 months, compared to 1.5 months with placebo, according to findings presented at the American Society of Clinical Oncology (ASCO) 2026 annual meeting.
Selpercatinib reduce el riesgo de recidiva en el cáncer de pulmón de células no pequeñas RET-positivo en estadio temprano
Selpercatinib en adyuvancia mejora la sobrevida libre de eventos (SLE) en pacientes con cáncer de pulmón de células no pequeñas (CPCNP) en estadio temprano y con fusión RET positiva que se han sometido a cirugía definitiva o radioterapia, según los resultados del primer ensayo de fase 3 en el que se utilizó un inhibidor de RET como terapia adyuvante.
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
Most anticancer drugs that enter clinical testing in children and adolescents fail to reach late-phase trials or earn pediatric regulatory approval, according to the authors of new research. Over a 15-year period, only 17.7% of anticancer drugs that entered pediatric-eligible clinical trials advanced to a pediatric phase 3 trial. The 10-year cumulative incidence of pediatric FDA approval was just 12.0% compared with 38.7% for adult FDA approval over the same window.
Targeted Blood Filtration to Remove sFlt-1 Can Prolong Pregnancy in Very Preterm Preeclampsia
Filtering a key protein from maternal blood may be a safe way to extend pregnancy in cases of very preterm preeclampsia, based on results of a first-in-human pilot study. Selectively removing soluble Fms-like tyrosine kinase 1 (sFlt-1) — a central mediator of preeclampsia — from maternal blood was associated with modestly reduced maternal blood pressure and 10 days of additional pregnancy time, reported lead author Ravi Thadhani, MD, of Cedars-Sinai Medical Center, Los Angeles, and colleagues.
Can Exercise Extend Survival After Breast Cancer?
Breast cancer survivors who maintain an exercise routine suited to their personal needs may improve their long-term survival, a new study suggests. The study, designed as a so-called target trial emulation, estimated that breast cancer survivors who start exercising regularly could see a reduction in their mortality risk over the next decade — up to 8 percentage points lower than if they simply received health-education materials.
El humo de los incendios forestales se relaciona con posibles riesgos de presentar algunos tipos de cáncer
Un análisis de datos de una cohorte prospectiva de más de 90.000 personas sugiere que la exposición al humo de los incendios forestales podría estar asociada con un mayor riesgo de padecer varios tipos de cáncer. Para determinar cómo esta contaminación generalizada podría estar afectando el riesgo de cáncer, el autor principal, Dr. Shuguang Leng, Ph. D., y su equipo de investigación analizaron datos del Ensayo de Detección de Cáncer de Próstata, Pulmón, Colon y Ovario (PLCO).
Daraxonrasib Combo Shows Promise in First-Line mPDAC
The investigational RAS inhibitor daraxonrasib has shown early promise in the first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) — though grade 3 or higher adverse events are common, according to a phase 1/2 trial. Among 39 patients who received daraxonrasib alongside standard chemotherapy, the objective response rate was 59%, with a disease control rate of 92% at a median of 10 months.
Locally Advanced Rectal Cancer Responds to HER2 Therapy
Combination therapy with two HER2 inhibitors plus chemotherapy could be a promising strategy for patients with locally advanced HER2-positive rectal adenocarcinoma, based on results of a small pilot study.
PSA Often Unchanged With Enzalutamide Progression
When men with advanced prostate cancer develop radiographic progression while taking enzalutamide, they frequently show little to no rise in prostate-specific antigen (PSA), according to a post hoc analysis of two clinical trials. Researchers found that among patients taking enzalutamide plus androgen deprivation therapy (ADT), about half of those who developed radiographic progression did so without a significant increase in PSA. And roughly 1 in 4 had no PSA rise at all.
Can a Machine Learning Model Predict Liver Cancer?
A machine learning model can accurately predict an individual’s risk of developing hepatocellular carcinoma (HCC) using routine clinical data, according to a new study. The findings point to a potential way to better identify patients for liver cancer screening, particularly those who fall outside current guidelines.
Neue Zahlen: Krebs schmälert Überlebensvorteil von Frauen in der Lebensmitte
Frauen leben statistisch länger als Männer. Doch dieser Vorsprung schrumpft im mittleren Lebensalter deutlich. Eine in JAMA Network Open veröffentlichte Kohortenstudie zeigt: Vor allem Brustkrebs und gynäkologische Tumoren treiben die Sterblichkeit bei Frauen zwischen 35 und 60 Jahren in die Höhe. Prävention, Aufklärung und individualisierte Früherkennung könnten entscheidend sein, um diese Entwicklung zu bremsen [1].
La ventaja de sobrevida femenina se reduce en la mediana edad debido al cáncer
Según un estudio de cohortes que analizó datos de 20 países y que abarca más de seis décadas de registros de mortalidad, los cánceres del aparato reproductor femenino contribuyeron sustancialmente a la mortalidad entre las mujeres de 35 a 60 años. El exceso constante de mortalidad por cáncer en comparación con los hombres de la misma edad se debió principalmente a los cánceres de mama y ginecológicos.
Priorities of Older Patients With Cancer: Is Anyone Listening?
Most older adults with advanced cancer care more about the quality of their remaining life than the quantity, but those priorities do not seem to alter their up-front care or their outcomes, according to a new study. The findings, published in JAMA Oncology, raise questions about whether oncology care teams are considering and responding to the personal goals of older patients with incurable cancers.
Mastectomía bilateral profiláctica en portadoras de mutaciones BRCA1/BRCA2: ¿reduce la mortalidad?
La mastectomía bilateral para reducir el riesgo disminuye drásticamente el riesgo de cáncer de mama en comparación con la vigilancia entre portadores de mutaciones BRCA1/2, pero aún no está claro si ese beneficio se extiende a una mejor sobrevida. Dos estudios recientes que intentaron aclarar esta relación llegaron a conclusiones diferentes.
Adding Protein EpiScores May Better Predict CRC Survival
DNA methylation-derived biomarkers called Protein EpiScores may improve the accuracy of disease-free and overall survival prediction in patients with colorectal cancer (CRC), compared with traditional clinical risk factors alone, suggest results of a prospective study. Although Protein EpiScores require further validation before they are ready for clinical use, the present data offer insights into the underlying processes shaping CRC outcomes, lead author Alicia R.
La presión arterial diastólica baja se asocia con colitis isquémica en mujeres mayores
El riesgo de colitis isquémica es más alto en mujeres mayores con presión arterial diastólica baja y en aquellas que toman al menos dos medicamentos antihipertensivos, según datos prospectivos de más de 100.000 participantes en Women’s Health Initiative.
Low Blood Pressure Linked With Colitis in Older Women
The risk for ischemic colitis (IC) is higher among older women with low diastolic blood pressure and those taking at least two antihypertensive medications, according to prospective data from more than 100,000 participants in the Women’s Health Initiative.
Poverty Linked to Worse Colorectal Cancer Survival
Lower socioeconomic status is associated with worse survival among patients with colorectal cancer (CRC), according to two recent studies published in JAMA Network Open.
New Mouse Model Supports Gut-Wall Origin of Celiac Disease
Data from a new mouse model support the long-standing hypothesis that celiac disease begins within the gut wall, as transglutaminase 2 (TG2)–specific B cells in Peyer’s patches sample perfused recombinant TG2 from the gut lumen and help ignite the autoimmune cascade that defines the disorder, according to investigators.
First AACR Pediatric Cancer Report Highlights Gains and Gaps
Children and adolescents with cancer are living longer than in previous decades, but progress has been uneven, according to the first American Association for Cancer Research (AACR) Pediatric Cancer Progress Report, released at a congressional briefing in Washington, DC. The 192-page report describes rapid growth in molecular diagnostics, targeted therapies, and cellular immunotherapies that are transforming outcomes for many patients.
US Advanced Breast Cancer Survival Up, Global Progress Lags
Patients in the US with advanced breast cancer (ABC) are living longer than a decade ago, but similar progress has lagged worldwide, according to findings presented at the Advanced Breast Cancer 8th International Consensus Conference (ABC8) in Lisbon, Portugal.
Pediatric Wilson’s Disease Carries Higher Risk of Worse Outcomes
FROM GASTRO HEP ADVANCES Children with Wilson’s disease (WD) are more likely than are adults to present with acute liver failure or acute-on-chronic liver failure and have lower transplant-free survival, according to data from a large single-center study in India. These findings underscore the importance of early recognition and genetic evaluation in pediatric patients, and timely consideration of liver transplantation in severe presentations, reported lead author Anand V.
Anti-TNF Exposure Influences Efficacy of Subsequent Therapies in UC
FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Prior exposure to tumor necrosis factor (TNF) antagonists may weaken the benefit of some advanced therapies for ulcerative colitis (UC) while enhancing the efficacy of others, based on results of a large meta-analysis.
Simpler Approach for Analysis of Timed Barium Esophagram
Interpreting timed barium esophagram (TBE) results with a multimetric classification tree is more accurate for identifying disorders of achalasia than conventional interpretation, according to investigators. The classification tree offers a practical alternative for evaluating esophagogastric junction (EGJ) outflow disorders when more advanced methods like high-resolution manometry (HRM) or functional lumen imaging probe (FLIP) panometry are unavailable, lead author Ofer Z.
Cancer Incidence, Mortality Climb in Lower-Income Countries
Over the past three decades, cancer mortality rates in higher-income countries fell approximately 30%, while rates in lower-income countries climbed about 15%, according to the most recent Global Burden of Disease (GBD) analysis. Similar disparities were observed in cancer incidence and disability-adjusted life-years (DALYs), suggesting that greater efforts are needed to address cancer across regions, lead author Lisa M. Force, MD, of the University of Washington, Seattle, and colleagues reported.
Sucralose Associated With Weaker Responses to Immunotherapy
New data may ignite debate about whether artificial sweeteners can alter the gut microbiome and, in turn, reduce how effective immunotherapy is in patients with cancer. A study in Cancer Discovery found that sucralose (Splenda) is associated with reduced efficacy of checkpoint inhibitor therapy in patients with cancer.
Large Language Models Cut Time, Cost of Guideline Development
FROM GASTROENTEROLOGY Large language models (LLMs) may help streamline clinical guideline development by dramatically reducing the time and cost required for systematic reviews, according to a pilot study from the American Gastroenterological Association (AGA).
Everolimus Plus Carboplatin Shows Promise in TNBC
Adding everolimus to carboplatin was associated with significantly increased progression-free survival (PFS) among patients with advanced triple-negative breast cancer (TNBC), according to a recent phase 2 study. The everolimus combination also had a manageable safety profile, according to lead author Rima Patel, MD, of Icahn School of Medicine at Mount Sinai, New York City, and colleagues.
High-grade Serous Carcinomas Follow Missed Salpingectomies
Opportunistic salpingectomy (OS) is feasible but not performed in almost a quarter of patients later diagnosed with high-grade serous carcinoma (HGSC), and about 40% of patients with a first-degree family history of ovarian cancer are not tested for genetic susceptibility prior to diagnosis, according to analysis of a retrospective review.
Enhanced Navigation Speeds Up Time to Radiotherapy in HNSCC
Enhanced navigation shortens time until guideline-adherent, postoperative radiotherapy (PORT) among patients with head and neck squamous cell carcinoma (HNSCC) compared with standard navigation, according to a study. The findings of the randomized controlled trial suggest that greater efforts are needed to develop and use enhanced, navigation-based approaches in this patient population, lead author Evan M.
Most GI Service Chiefs Support POCUS Training, But Uptake Is Slow
FROM GASTRO HEP ADVANCES Most GI service chiefs in the U.S. Veterans Affairs (VA) healthcare system support point-of-care ultrasound (POCUS) training, but fewer than half have the technology in their facility, according to a national survey.
IBD Medications Show No Link with Breast Cancer Recurrence
FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Medications for inflammatory bowel disease (IBD) appear to have no impact on risk of incident malignancies among patients with a history of breast cancer, according to investigators. These findings diminish concerns that IBD therapy could theoretically reactivate dormant micrometastases, lead author Guillaume Le Cosquer, MD, of Toulouse University Hospital, Toulouse, France, and colleagues, reported.
Sterile Water Bottles Deemed Unnecessary for Endoscopy
FROM GASTRO HEP ADVANCES Like diners saving on drinks, endoscopists can safely forgo sterile water in favor of tap, reducing both environmental and financial costs, according to a recent narrative review.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Will
Contact Will, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack